[Special Stock] NKMAX Achieves Complete Remission in Terminal Cancer Patients... World's First Solid Tumor NK Cell Therapy Clinical Results

[Asia Economy Reporter Hyungsoo Park] NK Max's stock price has been soaring for the second consecutive day. The news that the NK cell therapy under development showed effectiveness in treating late-stage sarcoma patients appears to have influenced the stock price.

At 9:09 a.m. on the 31st, NK Max was trading at 18,300 KRW, up 12.62% from the previous day. After hitting the daily price limit the day before, it has been on an upward trend for two consecutive days.

NK Max disclosed the interim results of Phase 1 clinical trials of the NK cell therapy being conducted in the United States on the 30th. Among 13 clinical trial subjects, 8 showed therapeutic effects, and one of them was diagnosed with a "complete remission" where the cancer completely disappeared.

For 13 late-stage sarcoma patients who were untreatable with existing drugs, NK Max's developed 'SNK01' was administered in combination with Merck and Pfizer's immuno-oncology drug 'Bavencio'. As a result, therapeutic effects were observed in 8 patients, recording a disease control rate (DCR) of 61.5%. Specifically, there was 1 complete remission (CR) and 2 partial remissions (PR) with more than 30% reduction in cancer cells. The clinical trial subjects were late-stage sarcoma patients untreatable with existing drug therapies, making these results remarkable.

Dr. Steven Cha, Chief Medical Officer of NKGEN Biotech, which conducted the clinical trial, emphasized, "This is the world's first result in solid tumor clinical trials using NK cells, and the astonishing complete remission in malignant sarcoma is an important achievement in the development of NK cell therapies." He added, "NK Max's SuperNK uses the patient's own cells in clinical trials, so graft-versus-host disease is not expected to occur even with repeated administration."

Park Sangwoo, CEO of NK Max, explained, "NK Max's therapy is effective not only for solid tumors but also did not cause significant side effects." NK Max plans to announce the results of Phase 1 and 2a clinical trials for lung cancer indications soon.

This content was produced with the assistance of AI translation services.